首页 正文

The Longer-Term Impact of Biosimilar Switching Policies in Patients With Inflammatory Bowel Disease in British Columbia, Canada: A Retrospective, Population-Based Study

{{output}}
Background and aims: In 2019, British Columbia (BC) became the first jurisdiction in North America to introduce a mandatory non-medical switching (NMS) policy requiring patients with Crohn's disease (CD) and ulcerative colitis (... ...